Inactive Instrument

Press Releases Arbutus Biopharma Corp Nasdaq

Equities

CA87911B2093

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06/06	Arbutus Biopharma Says Imdusiran Plus VTP-300 Therapy Lowers HBsAg Levels in Trial	MT
06/06	Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Inherency Remains High Bar To Meet	26/06	AQ
Treatment with Arbutus Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels	07/06	AQ
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels	06/06	GL
Arbutus Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure	06/06	AQ
Arbutus Biopharma : Corporate Presentation - June 2024	05/06	PU
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure	05/06	GL
Arbutus to Participate in Jefferies Global Healthcare Conference	29/05	GL
Arbutus to Present Imdusiran Data at EASL Congress 2024	22/05	AQ
Arbutus to Present Imdusiran Data at EASL Congress 2024	22/05	GL
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value	20/05	AQ
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value	17/05	BU
Arbutus to Participate in Two Upcoming Investor Conferences	07/05	GL
Arbutus Biopharma : Corporate Presentation - May 2024	02/05	PU
Arbutus: Q1 Earnings Snapshot	02/05	AQ
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update	02/05	GL
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024	02/05	GL
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update	18/04	GL
Arbutus Biopharma : Corporate Presentation - April 2024	16/04	PU
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna	04/04	GL
Arbutus to Participate in Two Upcoming Investor Conferences	08/03	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arbutus Biopharma Corp Nasdaq

Equities

CA87911B2093

Press Releases

Filters